

12th

ANNUAL ACUTE
LEUKEMIA
MEETING 2023

From 5th to 7th
OCT

*In person
& virtual event*

DIRECTOR

Dr. Adolfo de la Fuente
MD Anderson Cancer Center Madrid, España

www.mdanderson.es/cursoleucemia

MDAnderson
~~Cancer~~ Center
Madrid • España



SCIENTIFIC COMMITTEE

Dr. Ángela Figuera

Hospital Universitario de La Princesa, Madrid, Spain

Dr. Valentín García Gutiérrez

Hospital Universitario Ramón y Cajal, Madrid, Spain

Dr. Guillermo García-Manero

MD Anderson Cancer Center Houston, USA

Dr. Adrián Mosquera

Hospital Clínico Universitario, Santiago de Compostela, Spain

Dr. Mayte Olave

Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain

Dr. Joaquín Sánchez

Hospital Universitario Reina Sofía, Córdoba, Spain

Dr. Mar Tormo

Hospital Clínico Universitario de Valencia, Spain

Dr. David Valcárcel

Hospital valle de Hebron Barcelona. Institute of Oncology, Hospital Quirónsalud Barcelona, Spain

Dr. Claudio Cerchione

IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST, Meldola, Italy

Dr. Naval Daver

MD Anderson Cancer Center, Houston, USA

Dr. Alessandro Isidori

Marche Nord Hospital, Pesaro, Italy

Dr. Elias Jabbour

MD Anderson Cancer Center, Houston, USA

AMBASSADORS

Breno Moreno de Gusmão

Beneficência Portuguesa de São Paulo, São Paulo, Brasil

LATAM Ambassador

14:50 - 15:00

WELCOME

15:00 - 16:00

MEET THE EXPERT 1 **Key points in the treatment of Polycythaemia Vera. Interactive clinical case study**

Chair:

Dr. Valentín García Gutiérrez, Hospital Universitario Ramón y Cajal, Madrid, Spain

16:00 - 16:55

SESSION 1 **LMA 2 Target therapies - I**

Chairs:

Dr. Naval Daver, MD Anderson Cancer Center, Houston, USA

Dr. Adolfo de la Fuente, MD Anderson Cancer Center Madrid, Spain

16:00 - 16:20

Targeting IDH 1

Dr. Courtney DiNardo, MD Anderson Cancer Center, Houston, USA

16:20 - 16:40

FLT 3 inhibitors in relapse setting, biomarkers and mechanism of resistance

Dr. Naval Daver, MD Anderson Cancer Center, Houston, USA

16:40 - 16:55

Discussion

16:55 - 17:50

SESSION 2 ALL session

Chairs:

Dr. Elias Jabbour, *MD Anderson Cancer Center, Houston, USA*
Dr. Adolfo de la Fuente, *MD Anderson Cancer Center Madrid, Spain*
Dr. Alessandro Isidori, *Marche Nord Hospital, Pesaro, Italy*

16:55 - 17:15

Ph-positive, ready for Chemo-free approach

Dr. Elias Jabbour, *MD Anderson Cancer Center, Houston, USA*

17:15 - 17:35

Management of the elderly patient of ALL

Dr. María Calbacho, *Hospital Universitario 12 de Octubre, Madrid, Spain*

17:35 - 17:50

Discussion

17:50 - 18:10

Coffee break

18:10 - 19:25

SESSION 3 Diagnosis and preclinical management of leukaemia

Chairs:

Dr. Joaquín Sánchez, *Hospital Universitario Reina Sofía, Córdoba, Spain*
Dr. Adolfo de la Fuente, *MD Anderson Cancer Center Madrid, Spain*

18:10 - 18:30

ELN-2022 risk stratification and the challenge of working with two AML classifications

Dr. Jordi Sierra, *Hospital de la Santa Creu i Sant Pau, Barcelona, Spain*

18:30 - 18:50

MRD determination and treatment algorithms

Dr. Eva Barragán, *Hospital Universitario y Politécnico La Fe, Valencia, Spain*

18:50 - 19:10

Ex-Vivo tridimensional models for drug-sensitivity studies in AML

Dr. Juana Serrano, *Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain*

19:10 - 19:25

Discussion

19:25 - 20:25

DISCUSSION Induction therapy in transplant candidates. Intensive chemotherapy versus venetoclax-based therapy

Chairs:

Dr. Mar Tormo, *Hospital Clínico Universitario de Valencia, Spain*
Dr. Ángela Figuera, *Hospital Universitario de La Princesa, Madrid, Spain*
Dr. Adolfo de la Fuente, *MD Anderson Cancer Center Madrid, Spain*
Dr. Guillermo García-Manero, *MD Anderson Cancer Center, Houston, USA*

Transplant candidate patient Intensive Induction

YES - Dr. Josefina Serrano, *Hospital Universitario Reina Sofía, Córdoba, Spain*
NO - Dr. Jordi Esteve, *Hospital Clínic de Barcelona, Spain*

Discussion

08:30 - 09:25

SESSION 4 Myelodysplasia 1

Chairs:

Dr. Guillermo García-Manero, MD Anderson Cancer Center, Houston, USA
Dr. Mar Tormo, Hospital Clínico Universitario de Valencia, Spain

08:30 - 08:50

Altered pathways and target therapies in MDS

Dr. Joaquín Sánchez, Hospital Universitario Reina Sofía, Córdoba, Spain

08:50 - 09:10

Treatment of CCUS

Dr. Guillermo García-Manero, MD Anderson Cancer Center, Houston, USA

09:10 - 09:25

Discussion

09:25 - 10:40

SESSION 5 Chronic myeloproliferative neoplasms

Chairs:

Dr. Valentín García Gutiérrez, Hospital Universitario Ramón y Cajal, Madrid, Spain
Dr. Adolfo de la Fuente, MD Anderson Cancer Center Madrid, Spain

09:25 - 09:45

New developments in the management of myelofibrosis

Dr. Valentín García Gutiérrez, Hospital Universitario Ramón y Cajal, Madrid, Spain

09:45 - 10:05

Management of advanced stage chronic myeloid leukaemia

Dr. Guillermo Ortí, Hospital Universitario Vall d'Hebron, Barcelona, Spain

10:05 - 10:25

aCML and CNL. Diagnostic approach and treatment

Dr. Gonzalo Carreño, Hospital Universitario 12 de Octubre, Madrid, Spain

10:25 - 10:40

Discussion

10:40 - 11:10

Coffee break

11:10 - 12:25

SESSION 6 Immunotherapy

Chairs:

Dr. Alessandro Isidori, Marche Nord Hospital, Pesaro, Italy
Dr. Adolfo de la Fuente, MD Anderson Cancer Center Madrid, Spain

11:10 - 11:30

Driver mutations and immune microenvironment in AML

Dr. Antonio Curti, Azienda Ospedaliero-Universitaria di Bologna Policlinico S. Orsola, Bologna, Italy

11:30 - 11:50

Optimizing Transplant Approaches and Post-Transplant Strategies for Patients With Acute Myeloid Leukemia

Dr. Charles Craddock, Queen Elizabeth Hospital Birmingham, London, UK

11:50 - 12:10

Integration of immunotherapy into frontline

Dr. Elias Jabbour, MD Anderson Cancer Center, Houston, USA

12:10 - 12:25

Discussion

12:25 - 16:55

SESSION 7 LMA 2 Target therapies - II

12:25 - 12:45

Targeting IDH 2

Dr. Adolfo de la Fuente, MD Anderson Cancer Center Madrid, Spain

12:45 - 13:05

FLT 3 Optimal approaches to frontline FLT3 mutated AML

Dr. Alessandro Isidori, Marche Nord Hospital, Pesaro, Italy

13:05 - 13:20

Discussion

13:20 - 15:00

Cocktail

14:00 - 15:00

MEET THE EXPERT 3 The mIDH1 AML patient ineligible for intensive chemotherapy: Treatment decisions and practical steps

Chair: Dr. Adolfo de la Fuente, MD Anderson Cancer Center Madrid, Spain

14:00 - 14:15

An update on data for the mIDH1 AML population
Dr. Courtney DiNardo, MD Anderson Cancer Center, Houston, USA

14:15 - 14:30

Testing in time
Dr. Pau Montesinos, Hospital Universitario y Politécnico La Fe, Valencia, Spain

14:30 - 14:45

Case study
Dr. Susana Vives, Institut Català d'Oncologia, Badalona, Barcelona, Spain

14:45 - 15:00

Questions and Answers

Session sponsored by Servier

15:00 - 15:30

WORKSHOP Learning from the paediatrician

Chairs: Dr. Adolfo de la Fuente, MD Anderson Cancer Center Madrid, Spain
Dr. Mar Tormo, Hospital Clínico Universitario de Valencia, Spain

15:00 - 15:15

Monoclonals and CAR-T in ALL
Dr. Luis Madero, Hospital Universitario Quirónsalud, Madrid, Spain

15:15 - 15:30

Prevention and management of toxicities in ALL
Dr. David Díaz, Hospital Universitario Infantil Niño Jesús Madrid, Spain

15:30 - 16:45

MEET THE EXPERT 4 Targeting apoptosis. How we treat unfit patients and beyond

Chairs: Dr. Adolfo de la Fuente, MD Anderson Cancer Center Madrid, Spain
Dr. Joaquín Sánchez, Hospital Universitario Reina Sofía, Córdoba, Spain

15:30 - 16:00

VEN+HMA: long term outcomes, who does the best
Dr. Courtney DiNardo, MD Anderson Cancer Center, Houston, USA

16:00 - 16:30

Venetoclax combination for AML patients and Real world data
Dr. Yakir Moshe, Tel Aviv Sourasky Medical Center - Ichilov, Tel Aviv, Israel

16:30 - 16:45

Discussion

16:45 - 17:45

MEET THE EXPERT 5 Chronic Lymphocytic Leukemia

Chair: Dr. Adolfo de la Fuente, MD Anderson Cancer Center Madrid, Spain

Dr. Felipe Casado, Hospital General Universitario de Toledo, Spain

17:45 - 18:15

Coffee break

18:15 - 18:45

KEYNOTE LECTURE

Chairs: Dr. Joaquín Sánchez, Hospital Universitario Reina Sofía, Córdoba, Spain
Dr. Adolfo de la Fuente, MD Anderson Cancer Center Madrid, Spain
Dr. Naval Daver, MD Anderson Cancer Center, Houston, USA
Dr. Guillermo García-Manero, MD Anderson Cancer Center, Houston, USA
Dr. Alessandro Isidori, Marche Nord Hospital, Pesaro, Italy

What to do after 1 CR in patients between 65 al 75 yo?

An open discussion of options
Dr. Ángela Figuera, Hospital Universitario de La Princesa, Madrid, Spain

18:45 - 20:00

SESSION 8 Transplantation in acute leukemia

Chairs: Dr. Ángela Figuera, Hospital Universitario de La Princesa, Madrid, Spain
Dr. Adolfo de la Fuente, MD Anderson Cancer Center Madrid, Spain

18:45 - 19:05

Graft versus host (GVH) disease and leukemia free survival, can we achieve this?

Dr. Javier Bolaños, Sidney Kimmel Comprehensive Cancer Centre at Johns Hopkins, Baltimore, USA

19:05 - 19:25

AML with 10-20% blasts, induction or direct HSCT? Options
Dr. David Valcárcel, Institute of Oncology, Hospital Quirónsalud Barcelona, Spain

19:25 - 19:45

Immune based approaches in AML: CART, NK cell, bispecifics moving to the next chapter

Dr. Naval Daver, MD Anderson Cancer Center, Houston, USA

19:45 - 20:00

Discussion

08:30 - 09:45

SESSION 9 The challenge of maintenance in Acute Myeloid Leukemia. Meet the expert sessions

Chair: Dr. Pau Montesinos, *Hospital Universitario y Politécnico La Fe, Valencia, Spain*

08:30 - 08:50

Immunotherapy maintenance

Dr. Kristoffer Hellstrand, *University of Gothenburg, Göteborg, Sweden*

Chair:

Dr. Ángela Figuera, *Hospital Universitario de La Princesa, Madrid, Spain*

08:50 - 09:10

Oral Azacitidine maintenance

Dr. Adolfo de la Fuente, *MD Anderson Cancer Center Madrid, Spain*

Chair:

Dr. Alessandro Isidori, *Marche Nord Hospital, Pesaro, Italy*

09:10 - 09:30

FLT-3 inhibitors maintenance

Dr. Andrius Žučenka, *Vilnius University Hospital Santaros Klinikos, Vilna, Lithuania*

09:30 - 09:45

Discussion

09:45 - 11:00

WORKSHOP Blastic plasmacytoid dendritic cell neoplasm (BPDCN)

Chairs: Dr. Pau Montesinos, *Hospital Universitario y Politécnico La Fe, Valencia, Spain*
Dr. Adolfo de la Fuente, *MD Anderson Cancer Center Madrid, Spain*
Dr. Alessandro Isidori, *Marche Nord Hospital, Pesaro, Italy*

09:45 - 10:05

Characterisation and diagnosis

Dr. Claudio Cerchione, *IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST, Meldola, Italy*

10:05 - 10:25

Treatment of BPDCN

Dr. Josefina Serrano, *Hospital Univ. Reina Sofía, Córdoba, Spain*

10:25 - 10:45

Real-life experience and practical aspects

Dr. Pedro Paúl, *Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain*

10:45 - 11:00

Conclusions

11:00 - 11:30

Coffee break

11:30 - 12:45

SESSION 10 Artificial intelligence

Chairs:

Dr. Adrián Mosquera, *Hospital Clínico Universitario de Santiago, Santiago de Compostela, Spain*
Dr. Adolfo de la Fuente, *MD Anderson Cancer Center Madrid, Spain*

11:30 - 11:50

Computer vision for automatic diagnosis of AML from bone marrow smears

Dr. Jan-Niklas Eckardt, *University Hospital Carl Gustav Carus, Dresden, Germany*

11:50 - 12:10

Subclassification of primary and secondary AML based on genomic profiles using AI

Dr. Torsten Haferlach, *Munich Leukemia Laboratory, Munich, Germany*

12:10 - 12:30

Risk prediction in myelofibrosis and MDS with machine-learning tools

Dr. Adrián Mosquera, *Hospital Clínico Universitario de Santiago, Santiago de Compostela, Spain*

12:30 - 12:45

Discussion

12:45 - 13:40

SESSION 11 High Risk AML

Chairs:

Dr. Alessandro Isidori, *Marche Nord Hospital, Pesaro, Italy*
Dr. Claudio Cerchione, *IRCCS Istituto Romagnolo per lo Studio dei Tumori
"Dino Amadori" - IRST, Meldola, Italy"*

12:45 - 13:05

Management of high-risk AML

Dr. Pau Montesinos, *Hospital Universitario y Politécnico La Fe, Valencia, Spain*

13:05 - 13:25

Vyxeos in young patients with Secondary AML

Dr. Priyanka Mehta, *University Hospitals Bristol and Weston, Bristol, UK*

13:25 - 13:40

Discussion

13:40 - 14:35

SESSION 12 Myelodysplasia 2

Chairs:

Dr. David Valcárcel, *Institute of Oncology, Hospital Quirónsalud Barcelona, Spain*
Dr. Adolfo de la Fuente, *MD Anderson Cancer Center Madrid, Spain*

13:40 - 14:00

New approaches for anemia in MDS

Dr. Guillermo García-Manero, *MD Anderson Cancer Center, Houston, USA*

14:00 - 14:20

High risk MDS

Dr. Mar Tormo, *Hospital Clínico Universitario de Valencia, Spain*

14:20 - 14:35

Discussion

14:35 - 14:40

CLOSING Conclusions and closing

Dr. Adolfo de la Fuente, *MD Anderson Cancer Center Madrid, Spain*

EL RETO

Evaluators:

Dr. Adolfo de la Fuente, *MD Anderson Cancer Center Madrid, Spain*
Dr. María Ángeles Foncillas, *Hospital Universitario Infanta Leonor, Madrid, Spain*
Dr. Ana Alfonso, *Clínica Universidad de Navarra, Pamplona, Spain*

12th ANNUAL ACUTE LEUKEMIA MEETING

From **5th to 7th** OCT 2023

SPONSORS

PLATINUM

abbvie

 Bristol Myers Squibb™
Celgene | A Bristol Myers Squibb Company

 **SERVIER**
moved by you

GOLD

 **JD**
LABORATOIRES
DELBERT

 **Jazz** Pharmaceuticals.

 **MENARINI**
group

 **Stemline**
A Menarini Group Company

 **NOVARTIS**

 **SERB**
Pharmaceuticals

SILVER

 **astellas**

 **GSK**

 **LUZÁN CINCO**
health consulting

 **Pfizer**

BRONZE

 **BeiGene**

 **Daiichi-Sankyo**

 **SYROS**

COLABORATORS

 **AMGEN**

 **GILEAD** |  **Kite**

 **Incyte**

ORGANIZED BY

**MD Anderson
Cancer Center**
Fundación • España

ACCREDITATION

Credits requested from the Continuing Education Commission of Health Professions of the Community of Madrid

AUSPICE

 **SEHH** Sociedad Española de Hematología y Hemoterapia

VENUE

Auditorio Fundación MD Anderson Cancer Center Spain
C/ Arturo Soria 270. 28033 Madrid

STREAMING

TECHNICAL SECRETARY

 **doctaforum**
MEDICAL MARKETING SPECIALISTS

(+34) 91 372 02 03
e-mail: cursoleucemia@doctaforum.com
www.mdanderson.es/cursoleucemia